Heat treatment of Buruli ulcer

Prospectively registered Submission date Recruitment status 12/08/2008 No longer recruiting [] Protocol [] Statistical analysis plan Registration date Overall study status 29/08/2008 Completed [X] Results [] Individual participant data Last Edited Condition category 24/02/2009 Infections and Infestations

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Thomas Junghanss

Contact details

Section of Clinical Tropical Medicine
University Hospital Heidelberg
INF 324
Heidelberg
Germany
69120
Thomas.Junghanss@urz.uni-heidelberg.de

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers N/A

Study information

Scientific Title

Phase change material to treat Buruli ulcer through heat treatment: a prospective observational single centre proof-of-principle study

Study objectives

Buruli ulcer (BU) is a chronic necrotising disease of skin and soft tissue caused by Mycobacterium ulcerans. BU has been reported in more than 30 countries, but the major burden lies on children living in remote areas of West Africa associated with swamps and stagnant water bodies.

Heat has been shown to be effective in the treatment of BU in the early 70's. Based on these results, World Health Organization (WHO) guidelines listed the application of heat as a treatment option for BU. However, the heat application devices employed so far were impractical in most endemic countries. We developed a heat delivery device which is easy to apply, rechargeable in hot water, non-toxic and non-hazardous to the environment.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from:

- 1. Ethics Committee of the Medical Faculty Heidelberg (Ethikkommission der Medizinischen Fakultät Heidelberg [Germany]) on the 6th March 2006 (ref: 490/2005)
- 2. National Ethics Committee (Comite National D'Ethique [Cameroon]) on the 21st August 2006

Study design

Prospective observational single-centre study (proof-of-principle study)

Primary study design

Observational

Secondary study design

Other

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Buruli ulcer (BU)

Interventions

Phase change material as heat delivery system as part of a bandage which is applied to the Buruli ulcer and the surrounding tissue of the patient. Due to the properties of the bandage patients can move around freely during treatment.

Duration of heat treatment: 4 weeks (small ulcres and without significant oedema) and 6 weeks (large ulcers and/or significant oedema). Total duration of follow-up: 2 years.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

- 1. Small ulcers: complete healing (primary closure of ulcer)
- 2. Large ulcers: healing to a stage that patient can undergo skin grafting
- 3. Relapse rate over a follow up period of 2 years after completion of heat treatment

Secondary outcome measures

Histopathological changes in response to thermotherapy on day 28.

Overall study start date

28/02/2007

Completion date

27/02/2009

Eligibility

Key inclusion criteria

- 1. Patients (male and female) aged 6 21 years
- 2. Single ulcer clinically diagnosed as Buruli ulcer (WHO 2001)
- 3. Laboratory confirmation of Buruli ulcer: on day 0 four swabs from the undermined edges and one diagnostic biopsy from all patients enrolled into the trial on clinical grounds are taken. All samples are investigated by microscopy for acid-fast bacilli (AFB) after Ziehl Neelsen (ZN) staining and by IS2404 real-time polymerase chain reaction (PCR). Histopathological changes typical for BU are recorded.

Participant type(s)

Patient

Age group

Not Specified

Sex

Both

Target number of participants

10

Key exclusion criteria

In view of the unproblematic nature of the treatment no relevant adverse effects are foreseen. Nevertheless, patients with significant underlying other communicable and non-communicable diseases are excluded in this first proof-of-principle study.

Date of first enrolment

28/02/2007

Date of final enrolment

27/02/2009

Locations

Countries of recruitment

Cameroon

Germany

Study participating centre Section of Clinical Tropical Medicine

Heidelberg Germany 69120

Sponsor information

Organisation

University Hospital Heidelberg (Universitätsklinikum Heidelberg) (Germany)

Sponsor details

Im Neuenheimer Feld 672 Heidelberg Germany 69120

Sponsor type

Hospital/treatment centre

Website

http://www.med.uni-heidelberg.de/

ROR

https://ror.org/013czdx64

Funder(s)

Funder type

Industry

Funder Name

Volkswagen Foundation (VolkswagenStiftung) (Germany) (ref: I/81 308)

Alternative Name(s)

VolkswagenStiftung

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

Germany

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/03/2009		Yes	No